Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

Milton Packer,Stefan D. Anker,Javed Butler,Gerasimos Filippatos,Stuart J. Pocock,Peter E. Carson,James L. Januzzi,Subodh Verma,Hiroyuki Tsutsui,Martina Brueckmann,Waheed Jamal,Karen Kimura,Janet Schnee,Cordula Zeller,Daniel Cotton,Edimar Alcides Bocchi,Michael Böhm,Dong-Ju Choi,Vijay K. Chopra,Eduardo Chuquiure,Nadia Giannetti,Stefan Janssens,Jian Zhang,José Ramón González-Juanatey,Sanjay Kaul,Hans-Peter Brunner-La Rocca,Béla Merkely,Stephen J. Nicholls,Sergio V. Perrone,Ileana L. Piña,Piotr Ponikowski,Naveed Sattar,Michele Senni,Marie-France Seronde,Jindřich Špinar,Iain B. Squire,Stefano Taddei,Christoph Wanner,Faiez Zannad,EMPEROR-Reduced Trial Investigators

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

2020

Abstract Background Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure in patients regardless of the presence or absence of diabetes. More eviden...

Keywords:

in patient
Medicine
Heart failure
Cardiology
Diabetes mellitus
MEDLINE
Internal medicine
Empagliflozin

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

798

Citations